GvHD Induction using Immuno-Deficient Mouse Models engrafted with human PBMCs
PBMC from healthy donors are injected in NCG mice – Monitoring of the survival curve and Global clinical score
Exemple using Cyclosporine A treatment in n=12 mice per group (8-week old), 3 PBMCs donors randomised in the study.
- Cyclosporin-A treatment significantly reduced the mortality and the global clinical score as compared to the vehicle group (PBS)
- Circulating CD8+ T lymphocytes are decreased by Cyclosporin-A treatment
GVHD Global Clinical Scoring composed of six Scales:
Immuno Profiling post-GVHD Induction
Circulating CD8+ T cells are decreased by Cyclosporin A treatment (at D26)
Find out about our Disease Models:
- Cancer/Immuno-oncology/PDX
- Infection-HIV
- Inflammation – IBD
- Vaccine – Immunization
- GvHD
- Asthma
- Hu-liver
- Immuno-Safty – Toxicity (non-GLP)
- Models in development – Protocol design
HUMAN IMMUNE SYSTEM hu-mouse models
